Novo Nordisk Launches Ozempic® and Fiasp®, Expanding Treatment Options for Adults with Diabetes

February 5, 2018

Responsive image

PLAINSBORO, N.J., Feb. 5, 2018 /PRNewswire/ — Novo Nordisk today announced the availability of two new diabetes medications, Ozempic® (semaglutide) injection 0.5 mg or 1 mg and Fiasp® (insulin aspart injection) 100 Units/mL at pharmacies across the United States.

Ozempic® is a…

Category: Precious Metals